I'm still a bit surprised that there isn't a CVR along with this deal. I understand ONXX's reticence to ask for one, but AMGN now has a lot riding on carfilzomib and it's 3 in-progress trials. I think it's a good drug, and the royalties from the other programs should ease some nerves, but still...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.